Editas Medicine
EDIT
197 hedge funds and large institutions have $102M invested in Editas Medicine in 2025 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 46 increasing their positions, 60 reducing their positions, and 21 closing their positions.
416% more call options, than puts
Call options by funds: $3.54M | Put options by funds: $686K
38% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 21
3.3% more ownership
Funds ownership: 47.87% → 51.17% (+3.3%)
2% more funds holding
Funds holding: 194 → 197 (+3)
23% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 60
31% less capital invested
Capital invested by funds: $149M → $102M (-$46.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$5.09M |
| 2 |
BlackRock
New York
|
+$3.83M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.59M |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
+$2.95M |
| 5 |
D.E. Shaw & Co
New York
|
+$2.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$2.4M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.72M |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
-$1.55M |
| 4 |
Morgan Stanley
New York
|
-$1.18M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.02M |
EDIT Hedge Fund Activity: Q4 2025 in Review
197 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q4 2025, worth a combined $102M — down 31% from $149M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new EDIT positions and 21 closed out — a net gain of 8 holders — while 46 added to existing stakes and 60 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $5.09M. The largest seller was Bank of America, cutting an estimated $2.4M.
- 197 institutional investors held Editas Medicine (EDIT) as of Q4 2025, up from 194 in Q3 2025.
- Funds reported $102M of Editas Medicine stock for Q4 2025, down 31% quarter-over-quarter.
- 29 funds opened new Editas Medicine positions in Q4 2025 and 21 closed out, a net change of +8 holders.
- The largest Editas Medicine buyer in Q4 2025 was Renaissance Technologies, an estimated $5.09M added.
- The largest Editas Medicine seller in Q4 2025 was Bank of America, an estimated $2.4M sold.
Based on aggregated 13F filings for Q4 2025.